Engineering eukaryotic protein factories.
Ontology highlight
ABSTRACT: The biopharmaceuticals market is currently outperforming the pharmaceuticals market and is now valued at US$ 48 billion with an average annual growth of 19%. Behind this success is a 100-fold increase in productivities of eukaryotic expression systems. However, the productivity per cell has remained unchanged for more than 10 years. The engineering of the ER-resident protein folding machinery is discussed together with an overview of signal transduction pathways activated by heterologous protein overexpression to increase cell specific productivities.
SUBMITTER: Schroder M
PROVIDER: S-EPMC2151841 | biostudies-other | 2008 Feb
REPOSITORIES: biostudies-other
ACCESS DATA